CD274 and ovarian carcinoma: Phosphatidylinositol 3‐kinase gamma (PI3Kγ) inhibitor can sensitize the anti‐programmed death‐1/programmed death ligand‐1 (anti‐PD‐1/PD‐L1) response in ovarian cancer by modulating the PI3Kγ‐AKT‐NF‐κB pathway to remodel tumor immune microenvironment as an activated status, along with downregulating the expression of PD‐L1.